Clinical relevance of transgenic mouse models for aging research
Enns LC, Wiley JC, Ladiges WC.
Department of Comparative Medicine,
University of Washington, Seattle, WA 98195, USA.
Crit Rev Eukaryot Gene Expr. 2008;18(1):81-91.
ABSTRACTStudies on transgenic mice have shown them to be useful models for human aging- and age-related diseases. Life span end points in yeast and Caenorhabditis elegans can identify highly conserved genes that promote longevity when their functions are lost and which can readily be manipulated in the mouse. Protein kinase A is an example of a highly conserved gene that has age-delaying effects when specific subunits are suppressed or removed in the mouse, suggesting that loss of function may be a rational pharmacologic target. Gain of function is also an attractive clinical approach because expression levels of some vital genes may decrease in an age-related manner. The antioxidant enzyme catalase can delay aging when the human gene is inserted into mitochondria of mice. Other antioxidant genes are of interest in this system, both individually and in combination with catalase. A challenging aspect is to determine how to deliver catalase, as well as other gene products, into the mitochondria in the clinical setting. A number of new and exciting genes will most likely be investigated as clinical antiaging targets as the result of a forward genetic life span screening approach in invertebrates and a reverse genetic life span approach in the mouse.SENS
Caloric restriction mimetics
CR/age-related oxidative damage
Occupational success and longevity
Does resveratrol enhance longevity?
Resveratrol and vertebrate lifespan (PDF)
Extracellular glycation crosslinks: removal prospects
and further reading
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World
The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family